期刊
DIABETES OBESITY & METABOLISM
卷 17, 期 1, 页码 98-101出版社
WILEY-BLACKWELL
DOI: 10.1111/dom.12393
关键词
glycaemic control; remogliflozin etabonate; SGLT2; type 2 diabetes
The sodium-dependent glucose transporter 2 (SGLT2) inhibitor remogliflozin etabonate (RE) was evaluated in a 12-week, double-blind, randomized, placebo-and active-controlled, parallel-group study. A total of 252 newly diagnosed and drug-naive people with type 2 diabetes and glycated haemoglobin (HbA1c) concentrations of 7.0-<= 9.5% (53-80 mmol/mol) were recruited. Participants were randomized to RE (100, 250, 500 or 1000 mg once daily or 250 mg twice daily), placebo or 30mg pioglitazone once daily. The primary endpoint was change in HbA1c concentration from baseline. Secondary endpoints included changes in fasting plasma glucose, body weight and lipid profiles, safety and tolerability. We observed a statistically significant trend in the RE dose-response relationship for change from baseline in HbA1c at week 12 (p<0.047). RE was generally well tolerated and no effects on LDL cholesterol were observed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据